Neurogene : ASGCT NGN-401 Clinical Safety Poster

Preliminary Safety Results from the Ph1/2 Study of NGN-401, a Novel Regulated Gene Therapy for Rett Syndrome


Suter B1, Lieberman D2, Benke T3,...

Related Keywords

United States ,Texas ,Houston ,Colorado ,Jordan ,Boston ,Massachusetts ,New York ,Baylor College Of Medicine ,American ,Monroe Carell Jr ,Neurogene Inc ,Department Of Pediatrics ,Harvard Medical School ,American Society Of Gene ,Department Of Pediatrics Neurology ,Vanderbilt University Medical Center ,University Of Colorado School Medicine ,Department Of Neurology ,Preliminary Safety Results ,Novel Regulated Gene Therapy ,Rett Syndrome ,Texas Children ,Baylor College ,Boston Children ,Colorado School ,Hospital Colorado ,Anschutz Medical Campus ,Monroe Carell ,Toxicity Score ,Female Model ,Classic Rett ,Global Impression Severity ,Global Impression ,Syndrome Behavior Questionnaire ,May Indicate ,Cell Therapy ,Markets ,